BAP publishes guidance on the use of psychotropic medication before, during, and after pregnancy

Published: 03 May 2017

The British Association for Psychopharmacology (BAP) has published Consensus guidance on the use of psychotropic medication preconception, in pregnancy, and postpartum.

This evidence-based guideline evaluates the use of psychotropic drugs in patients with psychiatric disorders with respect to women in the perinatal period (between the preconception and postnatal period). It covers the main psychiatric disorders for which these drugs will be prescribed in adulthood with a focus on factors that influence treatment. The guideline aims to complement recommendation 1.4.3 of NICE Clinical Guideline 192 (Antenatal and postnatal mental health: clinical management and service guidance):

The BAP guideline covers a number of topics, including:

  • an overview of the guidance
  • risks of untreated illness in pregnancy
  • using medication in the perinatal period
  • benefits and harms associated with individual medications
  • recommendations for the pharmacological management of specific disorders.